Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 20/20 | 0.68 |
| ▸ | CCNT1 | O60563 | 19/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5662221 | 0.99 | CDK9 (0.67) | CDK9CCNT1 | |
| SCHEMBL14199808 | 0.84 | CDK9 (0.61) | CDK9CCNT1 | |
| SCHEMBL16051572 | 0.81 | CDK9 (1.00) | CDK9CCNT1 | |
| SCHEMBL2085336 | 0.81 | CDK9 (0.47) | CDK9CCNT1 | |
| SCHEMBL13994236 | 0.80 | CDK9 (0.54) | CDK9CCNT1 | |
| SCHEMBL16050612 | 0.79 | CCNT1 (1.00) | CDK9CCNT1 | |
| Hydrochloric Acid SCHEMBL5005714 | 0.78 | CDK9 (0.53) | CDK9CCNT1 | |
| SCHEMBL16052498 | 0.77 | CCNT1 (1.00) | CDK9CCNT1 | |
| SCHEMBL5001756 | 0.76 | CDK9 (0.51) | CDK9CCNT1 | |
| SCHEMBL29431058 | 0.75 | CDK9 (0.59) | CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233983-B2 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-01-12 | — | — | US | disclosed |
| US-9233983-B2 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-01-12 | — | — | US | disclosed |
| US-20150064196-A1 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof | IMPETIS BIOSCIENCES LIMITED (IN) | 2015-03-05 | — | — | US | disclosed |
| US-20150064196-A1 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof | IMPETIS BIOSCIENCES LIMITED (IN) | 2015-03-05 | — | — | US | disclosed |
| WO-2007067537-A1 | PYRROLOPYRIDINE KINASE INHIBITING COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | BMX, ERBB2, FRK | CDK9 392/4885CCNT1 1682/4885 |
| US-20150064196-A1 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof | BTK, MALT1, LCK | CDK9 121/4885CCNT1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.